MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
MacroGenics (MGNX) has scheduled its fourth quarter and full year 2024 financial results conference call for March 20, 2025, after market close. The biopharmaceutical company, which specializes in developing monoclonal antibody-based cancer therapeutics, will discuss financial performance and recent corporate developments during the call at 4:30 PM ET.
Participants can register in advance for the telephone conference, and a webcast will be available in the Investor Relations section of MacroGenics' website. The webcast recording will be archived for 30 days following the call.
MacroGenics (MGNX) ha programmato la sua conferenza telefonica sui risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 20 marzo 2025, dopo la chiusura del mercato. L'azienda biofarmaceutica, specializzata nello sviluppo di terapie oncologiche basate su anticorpi monoclonali, discuterà le performance finanziarie e i recenti sviluppi aziendali durante la chiamata alle 16:30 ET.
I partecipanti possono registrarsi in anticipo per la conferenza telefonica e sarà disponibile un webcast nella sezione Relazioni con gli Investitori del sito web di MacroGenics. La registrazione del webcast sarà archiviata per 30 giorni dopo la chiamata.
MacroGenics (MGNX) ha programado su conferencia telefónica sobre los resultados financieros del cuarto trimestre y del año completo 2024 para el 20 de marzo de 2025, después del cierre del mercado. La empresa biofarmacéutica, que se especializa en el desarrollo de terapias contra el cáncer basadas en anticuerpos monoclonales, discutirá el rendimiento financiero y los recientes desarrollos corporativos durante la llamada a las 4:30 PM ET.
Los participantes pueden registrarse con anticipación para la conferencia telefónica, y un webcast estará disponible en la sección de Relaciones con Inversores del sitio web de MacroGenics. La grabación del webcast se archivará durante 30 días después de la llamada.
MacroGenics (MGNX)는 2025년 3월 20일에 시장 종료 후 2024년 4분기 및 연간 재무 결과에 대한 전화 회의를 예정하고 있습니다. 단클론 항체 기반 암 치료제를 개발하는 생명공학 회사인 이 회사는 오후 4시 30분 ET에 회의 중 재무 성과 및 최근 기업 개발에 대해 논의할 것입니다.
참가자는 전화 회의에 미리 등록할 수 있으며, MacroGenics 웹사이트의 투자자 관계 섹션에서 웹캐스트를 이용할 수 있습니다. 웹캐스트 녹화는 회의 후 30일 동안 보관됩니다.
MacroGenics (MGNX) a programmé sa conférence téléphonique sur les résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 20 mars 2025, après la fermeture du marché. L'entreprise biopharmaceutique, spécialisée dans le développement de thérapies anticancéreuses basées sur des anticorps monoclonaux, discutera des performances financières et des récents développements d'entreprise lors de l'appel à 16h30 ET.
Les participants peuvent s'inscrire à l'avance pour la conférence téléphonique, et un webcast sera disponible dans la section Relations Investisseurs du site Web de MacroGenics. L'enregistrement du webcast sera archivé pendant 30 jours après l'appel.
MacroGenics (MGNX) hat seine Telefonkonferenz zu den finanziellen Ergebnissen des vierten Quartals und des gesamten Jahres 2024 für den 20. März 2025, nach Börsenschluss, angesetzt. Das biopharmazeutische Unternehmen, das sich auf die Entwicklung von krebsbekämpfenden Therapeutika auf Basis von monoklonalen Antikörpern spezialisiert hat, wird während der Konferenz um 16:30 Uhr ET über die finanzielle Leistung und aktuelle Unternehmensentwicklungen sprechen.
Teilnehmer können sich im Voraus für die Telefonkonferenz registrieren, und ein Webcast wird im Bereich Investor Relations der Website von MacroGenics verfügbar sein. Die Aufzeichnung des Webcasts wird 30 Tage nach der Konferenz archiviert.
- None.
- None.
ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET
Conference Call Information
To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.com. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
FAQ
When will MacroGenics (MGNX) release Q4 and full year 2024 earnings?
What time is MacroGenics (MGNX) Q4 2024 earnings call?
How can investors access MacroGenics (MGNX) Q4 2024 earnings call?
How long will MacroGenics (MGNX) Q4 2024 earnings call replay be available?
